# Beyond BMI: Who Actually Needs Treatment

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/beyond-bmi-who-actually-needs-treatment

> Among people all above BMI 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%. And in trial participants, weight loss was similar across risk groups, so treating by risk costs nothing in weight lost.

## Key points

- Ten-year cardiovascular mortality 5.7% to 0.1%, all above the same BMI cutoff.
- Weight loss was similar across baseline risk groups in SURMOUNT-1 participants.
- So allocating by risk rather than BMI costs nothing in weight lost; whether it does more good has not been tested.
- A prediction model, not a treatment trial, and the risk reduction is modeled, not observed.

Every insurer, every prescriber and every telehealth intake in this market decides who gets treatment using BMI. A study in Nature Medicine built a model from thousands of candidate features and showed what that threshold hides: among people all above a BMI of 27, ten-year cardiovascular mortality ranged from **5.7% to 0.1%**.[1] That is a fifty-seven-fold difference, and the number being used cannot see it. How obesity is defined today, BMI cut-offs included, is set out on our [obesity condition page](https://glpwatchdog.org/conditions/obesity).

## What the model does

Starting from thousands of tested features, the researchers identified the twenty most informative for predicting the future onset of eighteen obesity complications, and combined them into a single score. It stratified people into risk groups that behaved very differently over ten years, and it generalized to independent populations of both European and non-European ancestry.[1]

*Ten-year cardiovascular mortality by risk group, among people with BMI above 27.*

| Risk group | Cardiovascular mortality over 10 years |
| --- | --- |
| Highest | 5.7% |
|   | 1.8% |
| Middle | 0.9% |
|   | 0.4% |
| Lowest | 0.1% |

Everyone in that table meets the same BMI criterion. One group faces more than fifty times the risk of another, and the criterion cannot tell them apart.

## The finding that should change policy

The researchers then applied the score to participants in the SURMOUNT-1 tirzepatide trial and asked whether baseline risk predicted how well the drug worked.

> Weight loss was similar across baseline risk groups.

That sentence from the paper is the one that matters.[1] If the highest-risk people lose about as much weight as the lowest-risk people, then treating by risk rather than by BMI costs nothing in weight lost and should gain a great deal in benefit. The same drug, given to someone facing 5.7% cardiovascular mortality instead of someone facing 0.1%, should do far more good for the same money, although the paper did not test that directly.

Predicted risks also decreased following treatment with tirzepatide. That is a modeled decrease, not a count of observed events.

> **This bears directly on the rationing fights.** Coverage decisions in this market are made on BMI thresholds and cost, and the usual argument is about where to draw the line, which [many Asian countries already draw lower, at a BMI of 25](https://glpwatchdog.org/research/the-bmi-threshold-is-not-universal). This study suggests the line is drawn on the wrong axis: a BMI cutoff cannot distinguish a fifty-seven-fold difference in risk, and weight loss on the drug was about the same across all of it.

## What the study does not establish

- **It is a prediction model, not a treatment trial.** It identifies who is at risk. It does not demonstrate that allocating treatment by this score improves outcomes, which would require its own trial.
- **The risk reduction is modeled.** “Predicted risks decreased” means the score fell, not that events were counted.
- **Twenty features is still a lot to collect.** A score that outperforms BMI only when you have twenty inputs is harder to use than a number from a scale and a tape measure.
- **Three of the authors work for Eli Lilly, which makes tirzepatide.** One of them ran the SURMOUNT-1 analysis. The paper states that Lilly did not fund the study.[1]
- **It does not tell an individual what to do.** A risk group is a population, and our [note on averages](https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1) applies here as everywhere.

## Why BMI persisted anyway

BMI has real strengths. It is free, instant, requires no laboratory, and is calculable by anyone with a scale. That universality is exactly why it became the gate.

Its weaknesses are just as well known. It does not distinguish fat from muscle, distributes differently across populations, and says nothing about where fat sits or what it is doing metabolically. What is new here is a demonstration of how much risk information a BMI threshold discards, and evidence that acting on that information would cost nothing in treatment response.

## Frequently asked questions

### Is BMI a good way to decide who gets a GLP-1?

It hides an enormous amount. Among people all above a BMI of 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1% depending on other characteristics. That is a fifty-seven-fold difference the BMI threshold cannot see.

### Do higher-risk people respond better to treatment?

No, and that is the useful part. In SURMOUNT-1 participants, weight loss was similar across baseline risk groups. Since response does not vary much by risk, allocating treatment by risk rather than BMI costs nothing in weight lost and should produce far more benefit, though that has not been tested.

### Does this prove risk-based allocation works?

No. It is a prediction model, not a treatment trial. It identifies who is at risk without demonstrating that allocating treatment by the score improves outcomes. That would need its own study.

### Did the risk actually fall with treatment?

Predicted risk fell. That means the score decreased, not that events were counted in a follow-up period. It is a modeled improvement rather than an observed one, and the distinction matters.

### Why is BMI still used if it is this crude?

Because it is free, instant, needs no laboratory and anyone can calculate it. That universality is why it became the gate. What is new here is a measurement of how much risk information the threshold throws away.

## References

1. Demircan K, Carrasco-Zanini J, Williamson A, et al. Data-driven prioritization of high-risk individuals for weight loss interventions. Nature Medicine. 2026. PMID: 42062622. https://pubmed.ncbi.nlm.nih.gov/42062622/

---

Cite as: GLP Watchdog, Nora Bissett, "Beyond BMI: Who Actually Needs Treatment", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/beyond-bmi-who-actually-needs-treatment

Canonical HTML page: https://glpwatchdog.org/research/beyond-bmi-who-actually-needs-treatment

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
